Exploring the Long Term Safety, Tolerability and Clinical Effect of Laquinimod
- Study Title
- An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease
- Teva Identifier
- LAQ/5063OL | LAQ/5063 | 2005-004334-41
- ClinicalTrials.gov Identifier
- NCT00745615
- Study Status
- Terminated
- Trial Condition(s)
- Relapsing Remitting Multiple Sclerosis
- Interventions
- Drug: Laquinimod | Drug: Placebo
- Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult
- Age Range
- 18 Years to 50 Years
- Trial Duration
- December 7, 2005 - July 23, 2017
- Phase
- Phase 2
